Therapeutic suppression of Helicobacter pylori infection in C57BL/6J mice using specific polyclonal antibodies targeting BabA and FrpB4
Frontiers in Microbiology · 31.07.2026 · 17
DOI: 10.3389/fmicb.2026.1867770 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 31.07.2026. Verfasst von Lu Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School, Hebei Medical University, Shijiazhuang, China. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Current eradication therapies for Helicobacter pylori (H. pylori ) are increasingly compromised by the emergence of antibiotic resistance and adverse side effects. Exploration of non-antibiotic, targeted therapeutic alternatives is essential for effective H. pylori management.
Aim
To evaluate the therapeutic efficacy of a rationally designed specific antiserum targeting a BabA 189−244 -FrpB4 380−395 fusion peptide against H. pylori infection.
Methods
Using immunoinformatics, the Le b antigen binding domain of BabA (residues 189–244) and the immunogenic regions of FrpB4 (residues 380–395) were selected and synthesized as a fusion peptide. This engineered peptide was used to immunize rabbits to generate specific polyclonal antiserum. The direct antimicrobial effect was evaluated via an in vitro disk diffusion assay, and its impact on H. pylori adhesion to AGS (human gastric adenocarcinoma cell line) was assessed following bacterial pre-incubation with the antiserum. In vivo , C57BL/6J mice were inoculated intragastrically with H. pylori (1 × 10 9 CFU). After confirming bacterial colonization in the gastric mucosa, the infected mice (n=6 per group) received a daily oral administration of the antiserum (0.2 mL) for 2 weeks. Therapeutic efficacy was quantified via gastric bacterial load counting, urease activity measurement, and histological evaluation.
Results
Immunization with the BabA 189−244 -FrpB4 380−395 fusion peptide successfully elicited high-titer specific antibodies. In vitro , the antiserum significantly restricted H. pylori growth and reduced bacterial adherence to AGS cells ( P < 0.05). In vivo , 2 weeks of oral antiserum administration markedly reduced the gastric bacterial burden, suppressed mucosal urease activity ( P < 0.05), and attenuated histological colonization compared with untreated controls.
Conclusions
The specific antiserum targeting the BabA-FrpB4 fusion peptide exhibits significant antimicrobial and anti-adhesive activities against H. pylori , effectively restricting gastric colonization in vivo . This immunotherapeutic approach represents a viable non-antibiotic strategy for H. pylori intervention.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Graduate School, Hebei Medical University, Shijiazhuang, China.
- Department of Oncology, Hebei General Hospital, Shijiazhuang, China.
- Institute of Basic Medicine, Hebei Medical University, Shijiazhuang, China.
- Hebei Key Laboratory of Brain Science and Psychiatric-Psychologic Disease, The First Hospital of Hebei Medical University, Shijiazhuang, China.
- Department of Pathogenic Biology, Hebei Medical University, Shijiazhuang, China.
Zitieren
APA
Zhou, L., Wei, Y., Hu, J., Xue, Y., Nie, Y., Shi, Z., & Hu, D. (2026). Therapeutic suppression of Helicobacter pylori infection in C57BL/6J mice using specific polyclonal antibodies targeting BabA and FrpB4. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1867770
Vancouver
Zhou L, Wei Y, Hu J, Xue Y, Nie Y, Shi Z, et al. Therapeutic suppression of Helicobacter pylori infection in C57BL/6J mice using specific polyclonal antibodies targeting BabA and FrpB4. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.1867770
BibTeX
@article{Zhou2026,
author = {Zhou, Lu and Wei, Yusen and Hu, Jiapei and Xue, Yongxian and Nie, Yutong and Shi, Zhongli and Hu, Dailun},
title = {Therapeutic suppression of Helicobacter pylori infection in C57BL/6J mice using specific polyclonal antibodies targeting BabA and FrpB4},
journal = {Frontiers in Microbiology},
year = {2026},
volume = {17},
doi = {10.3389/fmicb.2026.1867770}
}
EUVIMED